Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE.
AZELASTINE HYDROCHLORIDE vs PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic through blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Phenylephrine is a direct-acting sympathomimetic amine that selectively stimulates α1-adrenergic receptors, causing vasoconstriction and nasal decongestion.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
Each 5 mL oral solution contains promethazine hydrochloride 6.25 mg and phenylephrine hydrochloride 5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL (8 teaspoonfuls) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
Promethazine: Terminal elimination half-life is approximately 10-14 hours in adults, ranging 5-14 hours; prolonged in hepatic impairment. Phenylephrine: Terminal elimination half-life is approximately 2-3 hours; clinically active for a shorter duration due to rapid metabolism.
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Promethazine: Renal excretion of metabolites and unchanged drug accounts for approximately 70-80% of elimination, with about 20-30% excreted in feces via biliary elimination. Phenylephrine: Primarily renal excretion as sulfate conjugates and unchanged drug; about 80% of a dose is excreted in urine within 48 hours, with minor fecal elimination (<10%).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic